Loading...
•
Dec 31, 2025
Aytu BioScience Q1 2026 Earnings Report
Reported lower revenue and a net loss driven by EXXUA launch investments in the fiscal second quarter.
Key Takeaways
Aytu BioPharma reported a decline in revenue and a net loss in fiscal Q2 2026 as the company increased investment to support the commercial launch of EXXUA, partially offset by stable performance in its ADHD portfolio.
Total net revenue declined year over year to $15.2 million.
ADHD portfolio remained the primary revenue contributor despite modest decline.
Net loss was driven largely by derivative warrant liability losses and launch investments.
Adjusted EBITDA turned negative due to EXXUA commercialization spending.
Revenue by Segment
Forward Guidance
The company expects EXXUA to become a key growth driver as commercialization progresses, while near-term profitability remains impacted by launch-related investments.
Positive Outlook
- Nationwide commercial launch of EXXUA completed.
- Sales force fully deployed and trained.
- EXXUA positioned in a large U.S. MDD market.
- ADHD portfolio continues to show relative stability.
- Strong patient access platform supports future growth.
Challenges Ahead
- Near-term profitability pressured by launch investments.
- Revenue decline in legacy pediatric portfolio.
- Exposure to derivative warrant valuation volatility.
- Marketing deemphasis impacting existing portfolios.
- Uncertainty around pace of EXXUA adoption.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...